Supernus Pharmaceuticals (SUPN) Cash & Equivalents (2011 - 2026)

Supernus Pharmaceuticals (SUPN) has 16 years of Cash & Equivalents data on file, last reported at $184.9 million in Q1 2026.

• On a quarterly basis, Cash & Equivalents rose 59.58% year-over-year to $184.9 million in Q1 2026; TTM through Mar 2026 was $184.9 million, a 59.58% increase from a year earlier, with the FY2025 full-year figure at $128.4 million, up 85.27% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $184.9 million, up from $128.4 million in the prior quarter.
• Over the last five years, Cash & Equivalents for SUPN reached as high as $184.9 million in Q1 2026 and fell as low as $24.7 million in Q2 2023.
• Historically, Cash & Equivalents has averaged $99.3 million across 5 years, with a median of $95.0 million in 2023.
• Across the five-year window, Cash & Equivalents slumped 85.75% in 2023 and soared 377.92% in 2025, its largest moves.
• Year by year, Cash & Equivalents stood at $93.1 million in 2022, then dropped by 19.4% to $75.1 million in 2023, then dropped by 7.63% to $69.3 million in 2024, then jumped by 85.27% to $128.4 million in 2025, then soared by 43.93% to $184.9 million in 2026.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $184.9 million in Q1 2026, $128.4 million in Q4 2025, and $151.4 million in Q3 2025.